CEPHALON PHASE II TRIALS OF MYOTROPHIN FOR POST-POLIO SYNDROME
Executive Summary
CEPHALON PHASE II TRIALS OF MYOTROPHIN FOR POST-POLIO SYNDROME are awaiting FDA approval, the company said May 6. Cephalon is planning four trials of insulin-like growth factor-1 for that indication. The syndrome is experienced by patients with previous paralytic poliomyelitis up to 30 years after their initial acute infection.